EHA 2022 | How does CAR-T therapy compare to stem cell transplantation?
Yi Lin
• 11 Jun 2022
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, shares some insights into the role of CAR-T therapy versus stem cell transplantation (SCT) in multiple myeloma and whether transplant will be replaced in the next five years. Dr Lin emphasizes the importance of the upcoming CARTITUDE-6 trial (NCT05257083), which will be comparing induction therapy followed by SCT and lenalidomide maintenance versus induction therapy followed by ciltacabtagene autoleucel (cilta-cel) and lenalidomide maintenance in patients with high-risk multiple myeloma, and will answer some very important questions in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
